Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients (SuparSDRF)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2017 by Guangdong General Hospital
Sponsor:
Information provided by (Responsible Party):
Wei Shi, Guangdong General Hospital
ClinicalTrials.gov Identifier:
NCT01468493
First received: October 29, 2011
Last updated: April 20, 2017
Last verified: April 2017
  Purpose
The purpose of this study is to determine whether the improved responsiveness to treatment achieved by CsA in patients with steroid-resistant or steroid-dependent FSGS could be explained by CsA's inhibitory action on the circulating suPAR expression.

Condition
FSGS

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective Controlled Follow-up of Serum Soluble Urokinase Receptor in the Cyclosporine A-treated Patients With Steroid-dependent and Steroid-resistant Focal Segmental Glomerulosclerosis

Resource links provided by NLM:


Further study details as provided by Guangdong General Hospital:

Primary Outcome Measures:
  • serum suPAR level when proteinuria reduction >=50% or complete remission [ Time Frame: 6 months after steriod alone or CsA plus steriod treatment ]
    serum suPAR level when proteinuria reduction of >=50% or complete remission occurs within <=6 months of steroid alone or CsA plus steroid treatment


Secondary Outcome Measures:
  • serum suPAR level after 6 months of steroid or CsA treatment without remission [ Time Frame: 6 months after steroid alone or CsA plus steroid treatment ]
    serum suPAR level after 6 months of steroid alone or CsA plus steroid treatment without remission


Estimated Enrollment: 90
Study Start Date: January 2011
Estimated Study Completion Date: January 2019
Estimated Primary Completion Date: January 2019 (Final data collection date for primary outcome measure)
Groups/Cohorts
steroid-sensitive FSGS
steroid-dependent and resistant FSGS
Healthy volunteers

  Eligibility

Ages Eligible for Study:   14 Years to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
1)the patients with steroid-sensitive FSGS;2)the cyclosporine A-treated patients with steroid-dependent and steroid-resistant FSGS;3)the healthy volunteers
Criteria

Inclusion Criteria:

  • Age at entry is between 14 and 70 years
  • biopsy-proven primary FSGS
  • proteinuria >=3 g/day
  • without corticosteroids or CsA treatment before entry

Exclusion Criteria:

  • Chronic Inflammatory Diseases
  • malignant tumor
  • diabetes mellitus
  • contraindications for the treatment of corticosteroids or CsA treatment
  • untolerate to or unwilling to accept corticosteroids or CsA treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01468493

Contacts
Contact: Wei Shi, MD,PhD 86-20-8385-0849 weishi_gz@126.com

Locations
China, Guangdong
Nephrology Dept.,Guangdong General Hospital Recruiting
Guangzhou, Guangdong, China, 510080
Contact: Wei Shi, MD,PhD    86-20-8385-0849    weishi_gz@126.com   
Sub-Investigator: Bin Zhang, MD,PhD         
Sub-Investigator: Ruizhao Li, MD         
Sponsors and Collaborators
Guangdong General Hospital
Investigators
Principal Investigator: Wei Shi, MD,PhD Nephrology Dept.,Guangdong General Hospital
  More Information

Responsible Party: Wei Shi, Director of renal division of Guangdong General Hospital, Guangdong General Hospital
ClinicalTrials.gov Identifier: NCT01468493     History of Changes
Other Study ID Numbers: GGH-1-1
Study First Received: October 29, 2011
Last Updated: April 20, 2017

Keywords provided by Guangdong General Hospital:
FSGS
suPAR

Additional relevant MeSH terms:
Glomerulosclerosis, Focal Segmental
Glomerulonephritis
Nephritis
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on April 28, 2017